Unapproved single-vial three-component peptide blend
GLOW
aka GLOW peptide blend · GHK-Cu + BPC-157 + TB-500
Goals: Recovery & injury · Skin & hair Compare with another peptide →
How it’s taken
Every route on record (2) with its dose range and source
| Route | Device | Status | Dose range | Source |
|---|---|---|---|---|
| Subcutaneous injection | — | User-reported | no dose range recorded | Reddit thread |
| Subcutaneous injection | Refillable multi-dose pen (unapproved use) | User-reported | no dose range recorded | Reddit thread |
“User-reported” means people describe taking it this way online. It is not a recommendation and not evidence that the route works. Handling and safety guide.
User reports
No user reports found. Both Reddit reads came back without countable reports for GLOW.
Summary
GLOW is a single-vial mixture of GHK-Cu + BPC-157 + TB-500, discussed for skin, tissue repair and inflammation claims. GLOW has three ingredients; KLOW adds KPV as a fourth. The mixture itself has no published human efficacy trial identified. Its full combination has never been tested together in a human trial found in this review. Clinical evidence overview; Combination literature search.
Evidence grade: D for the blend as sold, checked 2026-11-13. A component's evidence grade does not become the mixture's grade.
How it works proposed mechanisms, in plain words
-
Copper peptide component
GHK-Cu binds copper, but topical or laboratory findings do not establish benefits from this injected blend.
-
Repair component claims
BPC-157 and TB-500 have proposed tissue-repair effects, but the complete blend has no established human mechanism or benefit.
Mechanism in more detail
The proposed rationale combines separate component research on tissue repair and inflammation. It remains a hypothesis for the combined vial. Copper binding and formulation affect GHK-Cu's chemical state, while the TB-500 fragment cannot inherit clinical results from full-length thymosin beta-4. Metallopeptide review; FDA fragment review
Safety
- Blend-specific adverse-event frequencies and contraindications not established.
- Injectable peptide immunogenicity, aggregation and impurity concerns.
- Compatibility, copper speciation, potency and stability of the complete mixture not established.
- No validated clinical blend dosing range or storage lifetime found.
From labels, regulators and trials. No signal in small studies ≠ safe.
Legal status
US FDANot approved
Not approved; blend not covered by the single-API condition in the October HHS draft/interim peptide policy. July 23, 2026 PCAC favored BPC-157, TB-500 inclusion; these were ingredient recommendations, not approval of this blend. October HHS text requires a single API and omits GHK-Cu. The Federal Register calls it draft; finalization not found. GHK-Cu Category 1 is non-injectable only. Source
checked 2026-11-13WADA 2026Prohibited (S0)
Prohibited at all times because it contains BPC-157 (S0) and TB-500 (S2.3); blend name need not be listed. Source
checked 2026-11-13Evidence D skin, tissue repair and inflammation claims (the blend as sold)
No human trial of the complete GLOW blend was found; component studies and preclinical mechanisms do not establish the blend’s efficacy or safety.
No trial chart. No published human trial of the complete three-component blend was identified in the supplied research.
Human trials · 0
No human trials found for the marketed use.
Doses
Ranges from labels and studies, each with its route and source, then what Reddit users said they took. Not a recommendation.
No dose ladder. No validated dose, component ratio or complete-blend human trial identified.
What Reddit users said they took — user-reported, not advice: no range shown. No Reddit reports for this substance.
All dose ranges on record · 0
No label or study dose range on record.
Editorial ratings EDITORIAL
Editors’ judgement, 0–5. Opinion, not data; separate from grade and user score.
Sources
- hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf
- wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
- ema.europa.eu/en/medicines
Research checked 2026-11-13.